Clinical Prognosis of Keratin Family Genes in Patients with LUAD a Study Based on TCGA Database

Xia Liu
First Affiliated Hospital of Bengbu Medical College

Hangzhou Zhu
First Affiliated Hospital of Bengbu Medical College

Xiaojiu Zha
First Affiliated Hospital of Bengbu Medical College

Yan Rui
First Affiliated Hospital of Bengbu Medical College

Miao Li
First Affiliated Hospital of Bengbu Medical College

Linian Huang (✉ hlnbbmc@163.com)
The First Affiliated Hospital of Bengbu Medical College

Research

Keywords: lung adenocarcinoma, keratin, TCGA, prognosis.

Posted Date: September 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-864616/v1

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Malignant tumor is the main cause of death in the world, among which lung cancer is the main cause of death. The incidence rate and mortality of lung cancer are increasing year by year. This study aims to elucidate the potential prognostic value of keratin (KRT) gene family members in patients with lung adenocarcinoma (LUAD).

Materials and methods: RNA sequencing data were obtained from the Cancer Genome Atlas (TCGA) database of LUAD tumors and paired normal tissues. Multivariate Cox proportional hazards regression analysis was used to evaluate the prognostic value of KRT family member genes. Analyze the screening variables to construct the risk score. The time-dependent ROC curve is used to evaluate the predicted results. Finally, nomograms were used to assess individualized prognostic risk.

Result: From the differentially expressed genes, 14 KRT genes with significant imbalance in LUAD tumors and adjacent non-cancerous tissues were screened. Receiver operating characteristic curve (ROC) analysis confirmed that these 14 KRT genes can be used as potential diagnostic markers for the diagnosis of lung adenocarcinoma. Multivariate Cox regression analysis showed that six KRT genes were related to the prognosis of lung cancer. The variables were screened by multivariate Cox regression model. The final results showed that KRT8 and KRT6A were independent risk factors for the prognosis of lung adenocarcinoma.

Conclusion: KRT8 and KRT6A can be used as prognostic markers of LUAD. The high expression of KRT8 and KRT6A suggests that the prognosis of LUAD patients is poor.

Introduction

Malignant tumors are the leading cause of death worldwide, among which, lung cancer is the most(1, 2). According to statistics, the global incidence of lung cancer is about 2206771 new cases in 2020 and ranks second among all cancer incidences; With 1796144 deaths from lung cancer, ranking first among all cancer mortality, it is one of the leading causes of death, and its incidence and mortality are increasing year by year(3). Lung cancer is broadly divided into non-small cell lung cancer and small cell lung cancer, and the two main pathological types of non-small cell lung cancer are adenocarcinoma and squamous cell carcinoma. In recent years, the incidence of lung adenocarcinoma (LUAD) has increased year by year, which has exceeded the incidence of lung squamous cell carcinoma (LUSC). For LUAD, its occurrence and development are highly related to genetic factors, environment and other external factors. With the rise of next-generation gene sequencing technology (NGS), humans can acquire more valuable information through a deeper field of molecular biology, which undoubtedly gives more clues to the diagnosis and prognosis judgment of lung cancer and the discovery of new targets for treatment.

Using whole genome sequencing data combined with bioinformatics analysis is an effective way to explore the future molecular mechanism. The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov) is an open source project for mapping 38 human cancer genomes using large-scale genome
sequencing, including complete RNA sequencing (RNA SEQ) data for LUAD(1, 4, 5). A large number of studies have reported that keratin (KRT) family member genes are abnormally regulated in a variety of cancers, which can be used as biomarkers for cancer diagnosis and prognosis(6–8). Among them, keratin may be a new marker for the occurrence and development of lung adenocarcinoma. Keratins belong to the intermediate filament (IF) protein family expressed in all epithelial cells. As cytoskeletal proteins, IF proteins play an important role because they maintain the structural integrity of cells and tissues. These IF proteins are chemically stable long and unbranched filaments with a diameter of about 10 nm; Keratins are classified into type I acidic keratins and type II Basic keratins, which provide key structural support under mechanical and non-mechanical stress. The human keratin gene family consists of 54 genes with different functions(6, 9, 10). Previous studies have shown that multiple KRT family genes can be used as biomarkers for diagnosis and prognosis of epithelial malignancies (such as colorectal cancer, breast cancer, lung cancer, intrahepatic cholangiocarcinoma, pancreatic cancer, gastric cancer, etc.)(7, 8, 11, 12). In addition, previous studies have also reported that some KRT family genes can be used as prognostic indicators of LUAD(13–15). However, there is no report on the comprehensive and systematic analysis of KRT family genes in LUAD. At least as far as we know, its potential molecular mechanism still needs further study. The purpose of this study is to elucidate the potential molecular mechanism of KRT family member genes and determine their prognostic value in LUAD.

Results

1. Screening and co expression analysis of differential genes

RNA sequencing data of LUAD patients were downloaded from TCGA database, including 535 tumor tissue samples and 59 adjacent or normal tissue samples. A total of 501 LUAD patients had complete clinical outcome parameters and RNA SEQ data, which were included in the further study.

The differentially expressed genes belonging to KRT gene family were screened out. A total of 14 KRT genes were found to be significantly dysregulated in LUAD tumor and adjacent non cancer tissues. The differential expression fold changes and thermograms are shown in Fig.1 and Fig.2A. One KRT gene was down regulated, while the other genes were up-regulated. The specific expression is shown in Fig.3. Co-expression analysis showed that there was a certain co expression relationship between genes (Fig. 2B).

2. Prognostic screening of KRT gene

Univariate survival analysis of clinical parameters of overall survival (OS) time in patients with lung adenocarcinoma showed that tumor stage was significantly correlated with OS. Among them, 14 KRT genes were associated with the diagnosis of lung adenocarcinoma (Table 1). Multivariate Cox regression analysis showed that 6 KRT genes were correlated with the prognosis of lung cancer after correction of age, gender and stage (Table 2; KRT86 KRT81 KRT8 KRT18 KRT19 KRT6A). ROC curve analysis confirmed that these 14 KRT genes can be used as potential diagnostic markers for lung adenocarcinoma (Fig.4).

3. Construction of risk and prognostic gene signature in LUAD patients
Variables with p value less than 0.05 in Table 2 were further included in multivariate Cox regression analysis, covariates were included in gender, age and tumor stage, variables were screened by backward stepwise regression model based on maximum likelihood method. In the final regression model, age was retained (p = 0.057, HR = 1.015, 95% confidence interval 1.000-1.031), tumor stage (phase II, p < 0.001, HR = 2.109, 95% confidence interval 1.466-3.034; Phase III, p < 0.001, HR = 3.036, 95% confidence interval 2.063-4.469; Stage IV (p < 0.001, HR = 2.947, 95% confidence interval 1.631-5.324), KRT8 Cox regression results p < 0.001, HR = 1.001, 95% confidence interval 1.001-1.002; KRT6a Cox regression results p < 0.001, HR = 1.002, 95% confidence interval 1.001-1.003. The results showed that KRT8 and KRT6A were independent risk factors for the prognosis of lung adenocarcinoma. KRT8 and KRT6A were selected to construct risk score. The formula is risk score = KRT8 (expression) × β1 (regression coefficient) + KRT6A (expression) × β2 (regression coefficient), the construction formula of this study is: risk score = KRT8 (expression) × 0.001 + KRT6A (expression) × 0.002.

By establishing the lung cancer prediction model and constructing the multivariate Cox regression of the patient's risk score, it was found that the risk score was a significant independent risk factor (HR = 2.359, 95% CI 1.728-3.222, p < 0.001) (Fig.5).

K-M curve analysis showed that patients with high-risk score increased the risk of death (log rank p = 0.004, adjusted HR = 1.378, 95% CI 1.013-1.875, as shown in Fig.6A-D). The AUC change of time-dependent ROC curve shows that the risk score has a certain predictive value for all-cause death in patients with lung adenocarcinoma, and its AUC is roughly stable at about 0.6. With the change of time, the change of AUC is not obvious (Fig.6E).

4. Stratification and joint effect analysis

The relationship between clinical parameters and prognostic gene characteristics can be further studied through the comprehensive analysis of Norman map, stratification and combined effect analysis. For example, male patients with stage III disease and older than 65 years old are very likely to die of the disease, and their 1-year survival rate is almost zero. Nomograms constructed with risk scores and clinical LUAD parameters showed that prognostic markers based on KRT gene expression were more accurate than other parameters (Fig.7).

Discussion

Keratin KRT consists of most intermediate filaments IF. It is an important component of the cytoskeleton and participates in many cellular processes, including mitosis, differentiation, and apoptosis. Keratin is expressed in all epithelial cells and plays an important role in protecting epithelial cells from mechanical and non-mechanical damage. Keratin is divided into type I acidic keratin and type II basic keratin. KRT8 and KRT6a belong to type II keratin(7, 9, 16, 17). More and more studies have shown that KRT family genes can be used as markers for tumor diagnosis and prognosis, including KRT8 and KRT6A(7). However, this result is not surprising, because previous studies have confirmed the value of KRT gene in the diagnosis of lung adenocarcinoma(13, 14, 18). KRT8 is the main component of cytoskeleton
intermediate filaments and is mainly expressed in epithelial tissues (13). Studies have found that KRT8 is expressed in most cancers, such as breast cancer(12), renal cell carcinoma (19), gastric cancer(11), lung cancer (20) and so on. Compared with normal lung tissue, the expression of KRT8 was significantly increased in LUAD and LUSC, and the KRT8 high expression group in LUAD patients significantly reduced the overall survival rate (OS) and recurrence free survival rate (RFS) (13). Studies have shown that KRT8 is an important marker in the development process of primordial germ cells (PGCs), and KRT is necessary for PGCs migration. Compared with germ cells in gonads, PGCs in migrating mice express high levels of KRT8 during migration. Experiments have also proved that the lack of KRT8 leads to serious damage to human PGCs migration(21). Our study shows that KRT8 is highly correlated with the prognosis of lung cancer patients. Therefore, whether the high expression of KRT8 gene is related to the metastasis and differentiation of lung cancer cells in lung cancer tissues needs further research.

In addition, KRT6A is an important component in the formation of nail bed, filamentous papilla and oral mucosal epithelium (18), KRT6A is expressed in non-keratinized stratified squamous epithelial cells. In the pseudostratified epithelium of respiratory mucosa, KRT6A is highly up-regulated. In tumors, KRT6A is strongly expressed in squamous metaplasia in different parts, and its low expression can be occasionally found in adenocarcinoma (6). Previous studies have found that KRT6A can be used as a marker for the origin of breast cancer (22). The mutation of KRT6A can cause glutamate to be replaced by lysine in KRT6A, resulting in congenital thick nail (23, 24). KRT6A can also change the subtype of tumor associated macrophages in pancreatic ductal adenocarcinoma by participating in the modification of tumor associated macrophages (25). Some studies have also confirmed that the high expression of KRT6A in LUAD can promote the proliferation, migration and colony formation of lung adenocarcinoma cells, and can be used as a prognostic marker of LUAD (18, 26). However, this view is also controversial. Xiao Jian and others have reached different conclusions. The research suggests that KRT6A protein can inhibit the proliferation, migration and invasion of lung adenocarcinoma cells, and the high expression of KRT6A seems to be related to the good prognosis of lung adenocarcinoma patients(27). Studies have shown that high expression of KRT6A in patients with three negative breast cancer after adjuvant chemotherapy suggests better prognosis(28). Although this study is limited to cytological test and there is no further animal research and mechanism research, it may suggest that KRT6A has a potential beneficial effect. Therefore, we hope to have more mechanism research to find the role of KRT6A in lung adenocarcinoma.

It is worth mentioning that we creatively proposed this gene signature. We found that the gene signature constructed by the combination of these two genes for the diagnosis of lung cancer is very valuable for the diagnosis of lung cancer. At the same time, we also predict the prognosis of patients according to the gene expression of patients. However, our research also has many deficiencies. In the collected data, the clinical information of many patients is not perfect, including clinical examination results, drug dosage, treatment methods, etc. Secondly, the function of KRT8 and KRT6A genes and the mechanism of occurrence and prognosis in lung adenocarcinoma have not been further clarified. Therefore, we need to further study the clinical data of larger samples and improve the basic experiments to study its mechanism and authenticity.
Conclusions

Our study concluded that krt8 and krt6a could serve as prognostic markers for LUAD, and the high expression of krt8 and krt6a suggested a worse prognosis for LUAD patients.

Materials And Methods

1. Data sources

The RNA sequencing data set and clinical data of patients were collected from TCGA data base (https://portal.gdc.cancer.gov/). The RNA sequencing data is imported with default settings, and all values are normalized to FPKM values. This study does not include any experiments conducted by any author on human participants or animals. Since all data sets included in the current study were downloaded from TCGA database, and the acquisition and application of data were in accordance with the relevant provisions of TCGA database, no additional ethical review approval was required.

2. Screening and co expression of KRT differential genes

R software (version 4.0.3) was used to screen the obtained gene expression data for differential expression, and the screening standard was log2(FC) >1 or log2<1, and the average expression of FPKM > 1. Then, the KRT differential genes were selected from the differentially expressed genes. The heat map of differential expression was made by online tool heat mapper (http://www.heatmapper.ca/expression/). The GGCORR PLOT package was used to further display the differentially expressed genes, and the selected KRT differentially expressed genes were analyzed for co-expression. The co-expression relationship was considered statistically significant by Pearson test, with p < 0.05.

3. Prognostic and diagnostic value of KRT differential gene in lung adenocarcinoma

The screening criteria of clinical data are as follows: (1) the follow-up time must not be 0; (2) Patients must have sequencing data of tumor tissue. If a patient has sequencing data of multiple tumor samples, the tumor samples used for prognosis analysis will randomly retain a set of initial sampling and non-metastatic cancer sample data. The ROC curve module of Stata software was used to evaluate the diagnostic value of KRT differential genes in lung adenocarcinoma. The survival package of R language platform was used to evaluate the prognostic value of KRT family members by multivariate Cox proportional hazard regression analysis. Age, gender and tumor stage were included as covariates, and p < 0.05 was considered to be statistically significant. Finally, the genes with p value less than 0.05 in the previous multivariate Cox analysis were included in the multivariate Cox proportional hazards regression analysis. After adjusting for age, gender and tumor stage, the variables were screened by the backward stepwise regression model based on the maximum likelihood method.

4. Construct prognostic gene signature model
The genes with \( p < 0.05 \) in multivariate Cox regression analysis were used to construct gene signatures. Use the following formula: risk score = expression of KRT \( a \times \beta_a \) + expression of KRT \( b \times \beta_b \) + … expression of KRT \( n \times \beta_n \). The linear combination of regression coefficient (\( \beta \)) was obtained from multivariate Cox proportional hazards regression analysis. Patients were classified as low-risk or high-risk according to the median risk score. The survival ROC software package draws time-dependent ROC curves to evaluate the prediction results [28]. Finally, nomograms were used to assess the individual prognostic risk score.

**Abbreviations**

TCGA the Cancer Genome Atlas

KRT keratin

LUAD lung adenocarcinoma

LUSC lung squamous cell carcinoma

NGS next-generation gene sequencing technology

IF intermediate filament

OS overall survival

** Declarations**

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: Not applicable.

Competing interests: The authors declare that they have no competing interests.

Funding: This work has been supported by the Anhui Natural Science Foundation (2008085QH414).

Contribution: LX and ZHZ designed this study, analyzed the experiment and wrote a paper. ZXJ, RY and LM conducted data collection and analysis, and HLN revised the paper.

Acknowledgement: We are very grateful to LZB for his valuable comments on our research.

**References**

1. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82-93.
2. Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, et al. Lung Cancer in Republic of China. J Thorac Oncol. 2021;16(4):519-27.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

4. Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578(7793):112-21.

5. Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578(7793):102-11.

6. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129(6):705-33.

7. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30(2):127-38.

8. Kongara S, Kravchuk O, Teplova I, Lozy F, Schulte J, Moore D, et al. Autophagy regulates keratin 8 homeostasis in mammary epithelial cells and in breast tumors. Mol Cancer Res. 2010;8(6):873-84.

9. Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate Filaments as Effectors of Cancer Development and Metastasis: A Focus on Keratins, Vimentin, and Nestin. Cells. 2019;8(5).

10. Yi H, Yoon HN, Kim S, Ku NO. The role of keratins in the digestive system: lessons from transgenic mouse models. Histochem Cell Biol. 2018;150(4):351-9.

11. Guo D, Xu Q, Pabla S, Koomen J, Biddinger P, Sharma A, et al. Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein. Int J Mol Sci. 2018;19(2).

12. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-52.

13. Xie L, Dang Y, Guo J, Sun X, Xie T, Zhang L, et al. High KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients. Genes (Basel). 2019;10(1).

14. Wang W, He J, Lu H, Kong Q, Lin S. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis. Biosci Rep. 2020;40(7).

15. Yuanhua L, Pudong Q, Wei Z, Yuan W, Delin L, Yan Z, et al. TFAP2A Induced KRT16 as an Oncogene in Lung Adenocarcinoma via EMT. Int J Biol Sci. 2019;15(7):1419-28.

16. Li X, Song Q, Guo X, Wang L, Zhang Q, Cao L, et al. The Metastasis Potential Promoting Capacity of Cancer-Associated Fibroblasts Was Attenuated by Cisplatin via Modulating KRT8. Onco Targets Ther. 2020;13:2711-23.

17. Wang D, Zhang P, Xu X, Wang J, Wang D, Peng P, et al. Knockdown of cytokeratin 8 overcomes chemoresistance of chordoma cells by aggravating endoplasmic reticulum stress through PERK/eIF2α arm of unfolded protein response and blocking autophagy. Cell Death Dis. 2019;10(12):887.
18. Yang B, Zhang W, Zhang M, Wang X, Peng S, Zhang R. KRT6A Promotes EMT and Cancer Stem Cell Transformation in Lung Adenocarcinoma. Technol Cancer Res Treat. 2020;19:1533033820921248.

19. Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer. 2009;9:152.

20. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197-211.

21. Yu DCW, Wu FC, Wu CE, Chow LP, Ho HN, Chen HF. Human pluripotent stem cell-derived DDX4 and KRT-8 positive cells participate in ovarian follicle-like structure formation. iScience. 2021;24(1):102003.

22. Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, et al. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011;30(43):4399-409.

23. Abdollahimajd F, Rajabi F, Shahidi-Dadras M, Saket S, Youssefian L, Vahidnezhad H, et al. Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol. 2019;181(3):584-6.

24. Spaunhurst KM, Hogendorf AM, Smith FJ, Lingala B, Schwartz ME, Cywinska-Bernas A, et al. Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16. Br J Dermatol. 2012;166(4):875-8.

25. Zhang J, Sun H, Liu S, Huang W, Gu J, Zhao Z, et al. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma. Aging (Albany NY). 2020;12(22):23217-32.

26. Wang F, Chen S, Liu HB, Parent CA, Coulombe PA. Keratin 6 regulates collective keratinocyte migration by altering cell-cell and cell-matrix adhesion. J Cell Biol. 2018;217(12):4314-30.

27. Xiao J, Kuang X, Dai L, Zhang L, He B. Anti-tumour effects of Keratin 6A in lung adenocarcinoma. Clin Respir J. 2020;14(7):667-74.

28. Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, et al. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. Int J Cancer. 2015;136(8):1976-84.

Tables

Table 1. Clinical parameters of patients with LUAD from TCGA.
Table 2 Prognostic analysis of gene members of KRT family in patients with LUAD
| Protein | HR     | Low 95% CI | High 95% CI | P-value |
|---------|--------|------------|-------------|---------|
| KRT86   | 1.038  | 1.009      | 1.067       | 0.011   |
| KRT81   | 1.002  | 1.001      | 1.004       | 0.006   |
| KRT80   | 1.004  | 0.999      | 1.01        | 0.104   |
| KRT8    | 1.001  | 1.001      | 1.002       | <0.001  |
| KRT4    | 0.998  | 0.989      | 1.007       | 0.658   |
| KRT19   | 1.001  | 1.000      | 1.001       | 0.028   |
| KRT18   | 1.001  | 1.000      | 1.001       | <0.001  |
| KRT17   | 1.001  | 0.999      | 1.002       | 0.133   |
| KRT15   | 0.995  | 0.983      | 1.007       | 0.376   |
| KRT6B   | 0.997  | 0.979      | 1.015       | 0.734   |
| KRT6A   | 1.002  | 1.001      | 1.002       | <0.001  |
| KRT20   | 1.000  | 0.999      | 1.001       | 0.471   |
| KRT16   | 1.002  | 0.997      | 1.007       | 0.498   |
| KRT14   | 0.999  | 0.993      | 1.005       | 0.777   |

HR: hazard ratio. CI: confidence interval

**Figures**
Figure 1

Fold change of KRT gene family between LUAD tumor and adjacent normal tissue

A Heat map of KRT gene in LUAD tumor and adjacent normal tissues. B Heat map of co expression of KRT family genes in LUAD tumor tissue

Figure 2

A Heat map of KRT gene in LUAD tumor and adjacent normal tissues. B Heat map of co expression of KRT family genes in LUAD tumor tissue
Figure 3

Specific expression of 14 prognostic KRT family genes in LUAD tumors and adjacent normal tissues
Figure 4

The ROC curves of 14 prognostic KRT family genes in LUAD tumors and adjacent normal tissues
### Figure 5

Multivariate Cox results of risk score

|        | Hazard ratio (95% CI) | p-value |
|--------|-----------------------|---------|
| **Age** |                       |         |
| ≥65 (N=271) | 1                     |         |
| <65 (N=230) | 0.724 (0.538 - 0.974) | 0.0331 * |
| **Gender** |                       |         |
| Male (N=231) | 1                     |         |
| Female (N=270) | 0.958 (0.712 - 1.290) | 0.779   |
| **Stage** |                       |         |
| Stage I (N=271) | 1                     |         |
| Stage II (N=123) | 2.281 (1.587 - 3.278) | <0.001 *** |
| Stage III (N=81) | 3.196 (2.180 - 4.688) | <0.001 *** |
| Stage IV (N=26) | 3.373 (1.914 - 5.945) | <0.001 *** |

Risk Score (N=501) | 2.359 (1.728 - 3.222) | <0.001 *** |

# Events: 182; Global p-value (Log-Rank): 3.3717e-14
AIC: 1877.36; Concordance Index: 0.69
Figure 6

According to the prognostic risk score model of two KRT family genes in LUAD patients. They were divided into two groups from top to bottom A Risk score B Distribution of patient survival status C Heat map of expression of two prognostic KRT family genes between low and high-risk groups. D Kaplan-Meier curve for high and low risk groups. E ROC curve for predicting survival of LUAD patients according to risk score: AUC is the area under the curve
Figure 7

Nomogram prediction method for predicting 1-year and 5-year OS in LUAD patients